SRNE - ソレント・セラピュ―ティクス (Sorrento Therapeutics Inc.)

SRNEのニュース

   Sorrento Rejects Takeover Offer  2020/01/27 13:45:36 Benzinga Feeds
Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) announced on Monday, after reviewing the latest acquisition proposal in consultation with its advisors, is rejecting a takeover bid. According to Reuters , the company rejected a proposal by a private equity fund for a majority or all of its outstanding shares that had valued the drug developer at as much as $993 million. The Week Ahead In Biotech: … Full story available on Benzinga.com
   Sorrento Shares Soar On Disclosure Of Takeover Interest At Over 100% Premium  2020/01/10 16:07:50 Benzinga
Shares of small-cap biopharma Sorrento Therapeutics Inc (NASDAQ: SRNE ) were advancing strongly Friday. Sorrento, which is engaged in the development of new therapies to turn malignant cancers into manageable and possibly curable cancers, said it has received a non-binding proposal from a private equity fund to acquire a majority stake or the entire company for up to $7 per share. The upper range of the offer represents a 105% premium over the stock's Thursday closing price. Sorrento said its board is reviewing the proposal to determine … Full story available on Benzinga.com
   Sorrento shares rise on private equity proposal  2020/01/10 13:30:00 MarketWatch
Shares of Sorrento Therapeutics Inc. soared 47% in premarket trading on Friday on heavy volume after the company said it received an offer from an unnamed…
   Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps  2019/11/27 02:32:00 Zacks Investment Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
   Sorrento Therapeutics Investors Applaud Rejection Of Takeout Bid, Sell-Side Sees 700% Upside Potential  2019/11/26 16:25:27 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares are on a roller coaster ride after the company turned down an unsolicited, non-binding offer Monday from two biopharma companies to acquire all outstanding stock at $3-$5 per share in cash. The actively traded, small-cap biotech's shares were pulling back Tuesday after nearly doubling in the previous session. Takeout Offer Received And Rejected The offer rejected by Sorrento represented a roughly 88% to 331% premium to the $1.16 at which the shares closed Friday ahead of the company making the approach public. Sorrento said the offer, which was made Nov. 23, signficantly undervalued the company and was not in its best interest, leading … Full story available on Benzinga.com
   Sorrento Rejects Takeover Offer  2020/01/27 13:45:36 Benzinga Feeds
Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) announced on Monday, after reviewing the latest acquisition proposal in consultation with its advisors, is rejecting a takeover bid. According to Reuters , the company rejected a proposal by a private equity fund for a majority or all of its outstanding shares that had valued the drug developer at as much as $993 million. The Week Ahead In Biotech: … Full story available on Benzinga.com
   Sorrento Shares Soar On Disclosure Of Takeover Interest At Over 100% Premium  2020/01/10 16:07:50 Benzinga
Shares of small-cap biopharma Sorrento Therapeutics Inc (NASDAQ: SRNE ) were advancing strongly Friday. Sorrento, which is engaged in the development of new therapies to turn malignant cancers into manageable and possibly curable cancers, said it has received a non-binding proposal from a private equity fund to acquire a majority stake or the entire company for up to $7 per share. The upper range of the offer represents a 105% premium over the stock's Thursday closing price. Sorrento said its board is reviewing the proposal to determine … Full story available on Benzinga.com
   Sorrento shares rise on private equity proposal  2020/01/10 13:30:00 MarketWatch
Shares of Sorrento Therapeutics Inc. soared 47% in premarket trading on Friday on heavy volume after the company said it received an offer from an unnamed…
   Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps  2019/11/27 02:32:00 Zacks Investment Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
   Sorrento Therapeutics Investors Applaud Rejection Of Takeout Bid, Sell-Side Sees 700% Upside Potential  2019/11/26 16:25:27 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares are on a roller coaster ride after the company turned down an unsolicited, non-binding offer Monday from two biopharma companies to acquire all outstanding stock at $3-$5 per share in cash. The actively traded, small-cap biotech's shares were pulling back Tuesday after nearly doubling in the previous session. Takeout Offer Received And Rejected The offer rejected by Sorrento represented a roughly 88% to 331% premium to the $1.16 at which the shares closed Friday ahead of the company making the approach public. Sorrento said the offer, which was made Nov. 23, signficantly undervalued the company and was not in its best interest, leading … Full story available on Benzinga.com
   Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps  2019/11/27 02:32:00 Zacks Investment Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
   Sorrento Therapeutics Investors Applaud Rejection Of Takeout Bid, Sell-Side Sees 700% Upside Potential  2019/11/26 16:25:27 Benzinga
Sorrento Therapeutics Inc (NASDAQ: SRNE ) shares are on a roller coaster ride after the company turned down an unsolicited, non-binding offer Monday from two biopharma companies to acquire all outstanding stock at $3-$5 per share in cash. The actively traded, small-cap biotech's shares were pulling back Tuesday after nearly doubling in the previous session. Takeout Offer Received And Rejected The offer rejected by Sorrento represented a roughly 88% to 331% premium to the $1.16 at which the shares closed Friday ahead of the company making the approach public. Sorrento said the offer, which was made Nov. 23, signficantly undervalued the company and was not in its best interest, leading … Full story available on Benzinga.com
   Sorrento Therapeutics News: Why SRNE Stock Is Soaring 89% Today  2019/11/25 20:48:15 InvestorPlace
Sorrento Therapeutics (SRNE) news about the company receiving an unsolicited offer of acquisition has SRNE stock soaring on Monday.
   Sorrento Therapeutics Rejects Unsolicited Acquisition Proposal  2019/11/25 17:56:38 Investing News Network
Sorrento Therapeutics has announced it received — and rejected — an unsolicited all cash acquisition proposal from two companies. The post Sorrento Therapeutics Rejects Unsolicited Acquisition Proposal appeared first on Investing News Network .
   Sorrento Therapeutics surges as it rejects unsolicited all-cash offer  2019/11/25 12:54:58 Share Cast
Shares of Sorrento Therapeutics surged on Monday after the company said it had rejected an unsolicited buyout offer from two biopharmaceutical companies.

calendar